🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Beijing InnoCare Pharma Tech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Beijing InnoCare Pharma Tech as lead sponsor. Synced 26 Sep 2026
26Current trials
20Recruiting now
8Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Beijing InnoCare Pharma Tech is the lead sponsor of 26 current clinical trials in our China and USA registers. 20 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are ICP-248, Orelabrutinib and ICP-332. The most-studied condition is Relapsed or Refractory Mantle Cell Lymphoma (MCL).

ClinicalTrials.gov trials by status

  • Recruiting2077%
  • Not yet open415%
  • Active, closed28%

Trials by phase

  • Phase 2727%
  • Phase 1/2623%
  • Phase 1519%
  • Phase 3519%
  • Phase 2/3312%
01

Clinical trials sponsored by Beijing InnoCare Pharma Tech

26 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
NCT07378527 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria (CSU)
Drug: ICP-332
Phase 2/3 Recruiting 2026-02 China
ICP-332 in Subjects With Non-segmental Vitiligo
NCT07047612 · ClinicalTrials.gov ↗ · Non Segmental Vitiligo
Drug: ICP-332
Phase 2/3 Recruiting 2025-05 China
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (ICC)
Phase 2 Recruiting 2022-11 China
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
NCT05690581 · ClinicalTrials.gov ↗ · Advanced Solid Tumors and Hematologic Malignancies
Phase 1 Recruiting 2023-02 China
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Drug: ICP-332
Phase 3 Recruiting 2024-11 China
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226 · ClinicalTrials.gov ↗ · Solid Tumors
Phase 1/2 Recruiting 2020-09 China
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099 · ClinicalTrials.gov ↗ · Prurigo Nodularis (PN)
Phase 2 Recruiting 2025-11 USA, China
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494 · ClinicalTrials.gov ↗ · Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Phase 1 Recruiting 2024-12 USA, China
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138 · ClinicalTrials.gov ↗ · Hematologic Malignancies
Phase 2/3 Recruiting 2024-05 China
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06082102 · ClinicalTrials.gov ↗ · Relapsed/Refractory Marginal Zone Lymphoma
Phase 3 Recruiting 2023-12 China
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686 · ClinicalTrials.gov ↗ · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Drug: ICP-248
Phase 2 Recruiting 2025-08 China
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658 · ClinicalTrials.gov ↗ · Hematological Malignancies
Phase 1 Recruiting 2023-03 China
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
NCT07617493 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Recruiting 2026-07 China
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199 · ClinicalTrials.gov ↗ · Plaque Psoriasis Patients
Phase 3 Recruiting 2025-03 China
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
NCT07535099 · ClinicalTrials.gov ↗ · Health Services Research
Phase 1 Recruiting 2026-03 China
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05552937 · ClinicalTrials.gov ↗ · DLBCL
Phase 2 Recruiting 2021-09 China
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT07251998 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Drug: ICP-332
Phase 2 Recruiting 2025-12 China
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537 · ClinicalTrials.gov ↗ · Cutaneous Lupus Erythematosus (CLE)
Drug: ICP-488
Phase 2 Recruiting 2026-04 China
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
NCT05745623 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Phase 1/2 Recruiting 2022-12 China
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 · ClinicalTrials.gov ↗ · DLBCL
Phase 3 Recruiting 2024-05 China
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241 · ClinicalTrials.gov ↗ · Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Not yet open 2025-02 China
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
NCT07136558 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Not yet open 2025-08 China
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101 · ClinicalTrials.gov ↗ · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 3 Not yet open 2026-10 China
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
NCT07727486 · ClinicalTrials.gov ↗ · Primary Sjögren's Syndrome
Drug: ICP-488
Phase 2 Not yet open 2026-08 China
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT04014205 · ClinicalTrials.gov ↗ · Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
Phase 1/2 Active, closed 2019-11 USA
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
NCT05210868 · ClinicalTrials.gov ↗ · Hematoma
Phase 1/2 Active, closed 2021-11 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Beijing InnoCare Pharma Tech trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Beijing InnoCare Pharma Tech trials

27 conditions
Relapsed or Refractory Mantle Cell Lymphoma (MCL)2DLBCL2Prurigo Nodularis (PN)1Part 1:r/r B-cell Malignancies1Part 2:B-cell Malignancies1Acute Myelogenous Leukemia1Myelodysplastic Syndromes (MDS)1Chronic Spontaneous Urticaria (CSU)1Non Segmental Vitiligo1Intrahepatic Cholangiocarcinoma (ICC)1Advanced Solid Tumors and Hematologic Malignancies1Atopic Dermatitis1Relapsed or Refractory Non-Hodgkin Lymphoma1Solid Tumors1Advanced Solid Tumors1Hematologic Malignancies1Relapsed/Refractory Marginal Zone Lymphoma1Hematological Malignancies1Advanced Solid Tumor1Hematoma1Plaque Psoriasis Patients1Health Services Research1Plaque Psoriasis1Cutaneous Lupus Erythematosus (CLE)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2520
Clinical trials in USA32

A trial with sites in more than one country appears in each of those registers.

05

Questions about Beijing InnoCare Pharma Tech trials

How many clinical trials does Beijing InnoCare Pharma Tech sponsor?

Beijing InnoCare Pharma Tech is the lead sponsor of 26 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing InnoCare Pharma Tech trials recruiting?

Yes. 20 of its 26 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing InnoCare Pharma Tech testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are ICP-248 (5), Orelabrutinib (5), ICP-332 (4), ICP-488 (2) and Rituximab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.